Asthma is a chronic inflammatory disorder of the airways that is a major global burden on
both individuals and healthcare systems. Despite guideline-directed treatment, a significant …

Background Randomized controlled trials indicate that addition of a long-acting muscarinic
antagonist (LAMA) such as tiotropium may improve asthma control and reduce exacerbation …

Despite a range of efficacious therapies for asthma, including inhaled corticosteroids (ICS)
and long-acting β 2-agonists (LABA), a significant proportion of patients have poor asthma …

Despite major advances in therapeutic interventions and the availability of detailed
treatment guidelines, a high proportion of patients with symptomatic asthma remain …

Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the
management of asthma. Tiotropium bromide (Spiriva® Respimat®) is the only LAMA …

Objective Long-acting muscarinic antagonists (LAMAs) have been used in the treatment of
obstructive pulmonary diseases for years. Long-acting muscarinic antagonists were …

Short-acting muscarinic antagonists and tiotropium bromide have a well established role in
the treatment of different phases of asthma. Further data are needed to provide more …

Background Asthma is the most prevalent chronic airway disease observed in children and
adolescents, yet the variety of treatment options available for this age group is limited. With …

Introduction The objective of this paper is to systematically review the existing evidence of
the effectiveness and safety profile of a long-acting inhaled muscarinic antagonist as add-on …

Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory
effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy …